Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Veracyte, Inc.

< Previous 1 2 3 4 5 Next >
Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces First Quarter 2025 Financial Results
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Third Quarter 2024 Financial Results
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Second Quarter 2024 Financial Results
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
Tickers VCYT
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.